HCPCS Level II code J1440 designates a live fecal microbiota product, specified as "fecal microbiota, live - jslm, 1 ml." This biologic product is used as a therapeutic material for microbiome restoration and has growing clinical and coverage relevance as fecal microbiota therapies gain regulatory approvals and clinical adoption. Nationally, clear coding supports accurate billing, coverage determinations, and tracking of utilization for these novel biologic treatments.

Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this HCPCS Level II code maps to clinical service delivery, typical sites of service, and payer coverage context. The publication summarizes national benchmarks where available, common billing modifiers reported in practice, and policy developments that affect reimbursement and prior authorization practices. Clinical context on the product type and implications for procedural settings is provided to clarify where the code is typically used.

Intended for billing professionals, revenue cycle leaders, and clinical managers, the report explains coding nuances, payer considerations, and operational implications for integrating J1440 into billing workflows. Data not available in the input are noted where applicable.